ArticleCureus2026
Botryoid Rhabdomyosarcoma of the Uterine Cervix in a Young Adult: Diagnostic Challenge and Aggressive Clinical Course.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rhabdomyosarcoma of the cervix is an exceptionally rare malignancy in adults, typically presenting in pediatric populations. We report the case of a 26-year-old woman initially managed for a presumed benign endocervical polyp who subsequently developed rapidly progressive botryoid rhabdomyosarcoma of the uterine cervix. Initial histological misdiagnosis delayed appropriate treatment, and despite radical surgery, the patient experienced early recurrence with peritoneal dissemination. This case emphasizes the diagnostic challenges posed by the rarity of this tumor in adults, the importance of comprehensive immunohistochemical evaluation in ambiguous cervical lesions, and the aggressive biological behavior characteristic of rhabdomyosarcoma in adults. Confirmatory molecular testing for characteristic translocations should be considered to guide prognosis and therapy selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.